Presentation Material for the Third Quarter Financial Results for the Fiscal Year Ending March 2026

Overview of Performance

Consolidated performance for the third quarter of the fiscal year ending March 2026 showed net sales of 93,932 million yen (Year-over-Year +2.6%), operating income of 8,999 million yen (Year-over-Year +5.0%), and net income attributable to owners of the parent of 6,348 million yen (Year-over-Year +24.1%), achieving increased revenue and profit. The main driver was the growth of the Vision Care business, particularly due to increased supply of 1DAY contact lenses and expanded sales domestically and overseas. EBITDA also significantly increased to 16,514 million yen (Year-over-Year +12.7%), with margin improvement.

Segment Trends and Future Outlook

In the Vision Care segment, domestic sales under the MELS Plan, merchandise sales, and overseas sales of 1DAY products each increased, resulting in a 3.0% year-over-year sales increase. Meanwhile, Orthokeratology-related sales decreased due to economic stagnation in China, although there is an overall global expansion trend. The Healthcare & Life Care segment remained flat as a decline in the food business was offset by growth in composting-related business within Life Care. The full-year earnings forecast remains unchanged, with operating income expected at 10,200 million yen and net income at 5,800 million yen. Costs related to the start-up of the Malaysia plant and SG&A investments in 4Q are anticipated.